IHS Chemical Week

Regions :: Western Europe :: Germany

FDA issues warning letter to Boehringer Ingelheim API plant

4:39 AM MDT | May 22, 2013 | Deepti Ramesh

FDA issued a warning letter earlier this month to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facility Boehringer Ingelheim (Ingelheim am Rhein, Germany) at Ingelheim am Rhein for violations of cGMP. An FDA inspection of the facility from 5–12 November 2012 identified significant violations of cGMP for the manufacture of APIs and the cGMP regulations for finished pharmaceuticals, FDA says. The warning letter was published in the FDA website on 21 May. The violations for the manufacture of APIs at the Ingelheim am...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa